The Clinical Efficacy Of Transcutaneous Electrical Nerve Stimulation For Parkinson’s Disease Patients With Pain

Objective Observing the change of pain degree,quality of life,anxiety and depression in patients with Parkinson’s disease and chronic pain before and after the treatment of transcutaneous electrical nerve stimulation(TENS).To analyze the effect of TENS for the Parkinson’s disease patients with pain,and explore the clinical effective treatment of Parkinson’s disease with pain.Methods Prospective analysis of 119 Parkinson’s disease patients with pain who visit the neurology of the Second Hospital of Jiaxing during July 2016 and November 2017.Record their name,gender,age,duration,Unified Parkinson’s Disease Rating Scale score,Hoehn-Yahr Scale,Visual Analogue Scale(VAS)score,Self-rating Anxiety Scale(SAS)score,Self-rating Depression Scale(SDS)score and Brief Pain Inventory(BPI)score as the basic data.The subjects were randomly divided into control group and observation group according to the digital table method.The control group was treated with conventional drugs.The observation group was treated with conventional therapy combined TENS physical therapy of 2-5Hz stimulation,30 minutes /day.After 14 days,VAS,SAS,SDS and BPI were evaluated again and compared with each other.Results(1)A total of 119 Parkinson’s disease patients with pain were enrolled in this study,including 53 males and 66 females.All patients were randomly divided into two groups: the observation group(n = 58)and the control group(n = 61).(2)Before treatment,there was no significant difference between the observation group and the control group in the scores of VAS[(62.9±16.6)VS(58.9±17.8)],SAS[(53.4±11.1)VS(51.5±10.7)],SDS[(58.0±13.8)VS(55.8±12.7)] [all P>0.05].After treatment,the scores of VAS[(17.5±12.3)VS(36.2±14.7)],SAS[(41.2±10.1)VS(39.0±10.6)],SDS[(52.2±12.8)VS(51.2 ±12.1)] in both the observation group and the control group were significantly lower compared with those before treatment [all P<0.05].Compared with the control group,the observation group observed evidently lower scores in VAS(P <0.05).(3)In the assessment of BPI,there was no significant difference between the observation group and the control group in the scores of life pleasure[(5.0±3.1)VS(4.9±3.2)],daily living[(5.7±2.6)VS(5.1±3.0)],mood[(4.7±3.0)VS(4.4±3.4)],working[6.0±2.8)VS(5.0±3.2)],sleeping[(4.6±3.4)VS(3.9±3.5)],waiking ability[(4.0±3.8)VS(4.6±4.0)],and social communication[(3.6±3.2)VS(3.3±3.4)] [all P>0.05].After treatment,the scores of daily living[(2.3±1.9)VS(3.6±2.4)],working[(2.2±1.8)VS(3.6±2.5)],sleeping[(1.8±2.1)VS(2.9±2.9)],waiking ability[(1.7±2.1)VS(3.4±3.2)] in both the observation group and the control group were significantly lower compared with those before treatment [all P <0.05].Compared with the control group,the observation group observed evidently lower scores in daily living,working,sleeping and waiking ability[all P <0.05].Conclusion Both conventional anti-Parkinson’s disease drug therapy and combined TENS can improve pain,quality of life,anxiety and depression in Parkinson’s disease patients with pain,but the combination therapy is better than single drug therapy for improving pain and quality of life.